Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
NCT00439270Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2007
- Primary completion
- Feb 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in prostate cancer (PCa), sponsored by Bristol Myers Squibb. Started Jul 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00439270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439270.